Literature DB >> 12403657

First model of spontaneous vagal hyperreactivity and its mode of genetic transmission.

Angelo Livolsi1, Josiane Feldman, Josué Feingold, Laurence Weiss, Yves Alembik, Ismail M Sharifah-Anion, Michel Fischbach, Jean Messer, Pascal Bousquet.   

Abstract

BACKGROUND: The main purpose of our study was to define an animal model of vagal hyperreactivity and its genetic transmission. METHODS AND
RESULTS: We first investigated the vagal reactivity with phenylephrine in conscious rabbits. Barosensitivity and the maximal bradycardic response were measured at the upper mean blood pressure plateau. Hyperreactive (H) animals were selected and crossbred with normal (N) ones. Results showed no significant difference between calculated barosensitivity values after the different doses of phenylephrine. In contrast, an increase of the values and a great dispersion appeared 1 to 5 beats after the end of the ramp. Marked pauses (6000 to 20 000 ms) were obtained with some rabbits, which were blocked by atropine. A significant excess of hyperreactive offspring was observed in HxH crossings compared with NxN ones (39.4% male and 42.3% female offspring versus 14.4% and 4.4%, respectively). Few female offspring were hyperreactive compared with males in NxH and NxN crossings (4.1% versus 23.4% and 4.4% versus 14.4%, respectively).
CONCLUSIONS: This study describes the first model of spontaneous vagal pauses. The inheritance could be polygenic with a partial sex-limited character.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403657     DOI: 10.1161/01.cir.0000039155.49920.1f

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  1 in total

1.  Constitutive overexpression of muscarinic receptors leads to vagal hyperreactivity.

Authors:  Angelo Livolsi; Nathalie Niederhoffer; Nassim Dali-Youcef; Walid Mokni; Catherine Olexa-Zorn; Jean-Pierre Gies; Luc Marcellin; Josiane Feldman; Pascal Bousquet
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.